Investigators found the level of small nucleolar RNA host gene 1 (SNHG1) was significantly upregulated in prostate cancer tissues and cells. Knockdown of SNHG1 significantly suppressed proliferation, migration and invasion and promoted cell apoptosis in prostate cancer cells.
Scientists investigated the roles of U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) in the resistance to anti-androgen treatment in prostate cancer and its underlying mechanism.
[Biochemical and Biophysical Research Communications]
To investigate whether combined treatment with Enzalutamide (ENZ) and 3,3′-diindolylmethane (DIM) could overcome ENZ resistance by regulating Wnt signaling to inhibit androgen receptor signaling and EMT in ENZ-resistant prostate cancer cells, 22Rv1 cells were cultured in normal medium and treated with ENZ, DIM, and DIM with ENZ.
6630899 ZPCG49Z6 items 1 apa default asc 1
Tsao, C.-W., Li, J.-S., Lin, Y.-W., Wu, S.-T., Cha, T.-L., & Liu, C.-Y. (2021). Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line. Scientific Reports, 11(1), 1239. https://doi.org/10.1038/s41598-020-80519-3 Cite
Investigators observed that melatonin inhibited RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevented cancer-associated osteoclast differentiation.
6630899 FLJHJT5W items 1 apa default asc 1
Liu, P.-I., Chang, A.-C., Lai, J.-L., Lin, T.-H., Tsai, C.-H., Chen, P.-C., Jiang, Y.-J., Lin, L.-W., Huang, W.-C., Yang, S.-F., & Tang, C.-H. (2021). Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases. Oncogene, 1–13. https://doi.org/10.1038/s41388-020-01613-4 Cite
To determine how CD117 expression and activation by its ligand stem cell factor alters prostate cancer aggressiveness, researchers used C4-2 and PC3-mm human prostate cancer cells, which contained a CD117+ subpopulation.
6445212 5FRKQI8W items 1 apa default asc 1
Harris, K. S., Shi, L., Foster, B. M., Mobley, M. E., Elliott, P. L., Song, C. J., Watabe, K., Langefeld, C. D., & Kerr, B. A. (2021). CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. Scientific Reports, 11(1), 1465. https://doi.org/10.1038/s41598-021-81126-6 Cite
Scientists showed that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine (NE) transdifferentiation. In clinical prostate cancer (PC) samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with androgen receptor signaling.
6630899 V5I8BGNT items 1 apa default asc 1
Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., Bert, A. G., Winter, J. M., Iggo, R., Das, R., Obinata, D., Sandhu, S., Risbridger, G. P., Taylor, R. A., Lawrence, M. G., Butler, L. M., Zoubeidi, A., Gregory, P. A., Tilley, W. D., … Selth, L. A. (2021). Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports, 34(1). https://doi.org/10.1016/j.celrep.2020.108585 Cite
Investigators performed a direct, unbiased chemical genetic screen to identify pro-viral integration site for Moloney murine leukemia virus-1 (PIM1) substrates in prostate cancer cells.
6630899 EBLRNAU9 items 1 apa default asc 1
Ledet, R. J., Ruff, S. E., Wang, Y., Nayak, S., Schneider, J. A., Ueberheide, B., Logan, S. K., & Garabedian, M. J. (2021). Identification of PIM1 substrates reveals a role for NDRG1 phosphorylation in prostate cancer cellular migration and invasion. Communications Biology, 4(1), 1–12. https://doi.org/10.1038/s42003-020-01528-6 Cite
Researchers evaluated whether interactions between heterogenous populations could impact growth and response to radiotherapy in prostate cancer.
6630899 JVHEP6BS items 1 apa default asc 1
Paczkowski, M., Kretzschmar, W. W., Markelc, B., Liu, S. K., Kunz-Schughart, L. A., Harris, A. L., Partridge, M., Byrne, H. M., & Kannan, P. (2021). Reciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer. Communications Biology, 4(1), 1–13. https://doi.org/10.1038/s42003-020-01529-5 Cite
Direct targeted HSF1 inhibitor robustly inhibited the heat shock factor 1 cancer gene signature and prostate cancer cell proliferation. It potently attenuated tumor progression in four therapy-resistant prostate cancer animal models, including an neuroendocrine prostate cancer model, where it caused profound tumor regression.
[Science Translational Medicine]
6630899 2U7DRC6Y items 1 apa default asc 1
Dong, B., Jaeger, A. M., Hughes, P. F., Loiselle, D. R., Hauck, J. S., Fu, Y., Haystead, T. A., Huang, J., & Thiele, D. J. (2020). Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. Science Translational Medicine, 12(574). https://doi.org/10.1126/scitranslmed.abb5647 Cite
Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving the treatment of prostate cancer. Scientists describe molecular characterization and drug testing in a panel of 20 prostate cancer cell lines.
6630899 UK4B7Z5D items 1 apa default asc 1
Smith, R., Liu, M., Liby, T., Bayani, N., Bucher, E., Chiotti, K., Derrick, D., Chauchereau, A., Heiser, L., Alumkal, J., Feiler, H., Carroll, P., & Korkola, J. E. (2020). Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Scientific Reports, 10(1), 21750. https://doi.org/10.1038/s41598-020-78798-x Cite
The effects and molecular mechanisms of ASC‐J9 on various AR‐associated diseases are summarized. Importantly, the effects of ASC‐J9 and AR antagonists enzalutamide/bicalutamide on prostate cancer are compared in detail and crucial differences are highlighted.
[Chemical Biology & Drug Design]
6630899 4XXFRA7C items 1 apa default asc 1
Hu, H., Zhou, H., & Xu, D. (n.d.). A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. Chemical Biology & Drug Design, n/a(n/a). https://doi.org/https://doi.org/10.1111/cbdd.13811 Cite